SG11201902941UA - Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy - Google Patents
Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathyInfo
- Publication number
- SG11201902941UA SG11201902941UA SG11201902941UA SG11201902941UA SG11201902941UA SG 11201902941U A SG11201902941U A SG 11201902941UA SG 11201902941U A SG11201902941U A SG 11201902941UA SG 11201902941U A SG11201902941U A SG 11201902941UA SG 11201902941U A SG11201902941U A SG 11201902941UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- nephropathy
- immunoglobulin
- methods
- Prior art date
Links
- 208000010159 IgA glomerulonephritis Diseases 0.000 title abstract 3
- 201000001474 proteinuria Diseases 0.000 title abstract 3
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 abstract 2
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Environmental Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Diabetes (AREA)
- Animal Husbandry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662407979P | 2016-10-13 | 2016-10-13 | |
| US15/399,524 US10736960B2 (en) | 2016-01-05 | 2017-01-05 | Methods for inhibiting fibrosis in a subject in need thereof |
| US15/470,647 US20170253667A1 (en) | 2016-01-05 | 2017-03-27 | Methods for inhibiting fibrosis in a subject in need thereof |
| US201762527926P | 2017-06-30 | 2017-06-30 | |
| PCT/US2017/056386 WO2018071701A1 (en) | 2016-10-13 | 2017-10-12 | Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201902941UA true SG11201902941UA (en) | 2019-05-30 |
Family
ID=61906454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201902941UA SG11201902941UA (en) | 2016-10-13 | 2017-10-12 | Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP3525798A4 (pt) |
| JP (1) | JP6893554B2 (pt) |
| KR (1) | KR102348939B1 (pt) |
| CN (2) | CN116726163A (pt) |
| AU (1) | AU2017342428B2 (pt) |
| BR (1) | BR112019007426A2 (pt) |
| CA (2) | CA3039927C (pt) |
| CL (2) | CL2019000909A1 (pt) |
| GE (1) | GEP20247587B (pt) |
| IL (1) | IL265981A (pt) |
| JO (1) | JOP20190068A1 (pt) |
| MA (1) | MA46541A (pt) |
| MX (1) | MX2019004074A (pt) |
| PH (1) | PH12019500711A1 (pt) |
| SG (1) | SG11201902941UA (pt) |
| UA (1) | UA126908C2 (pt) |
| WO (1) | WO2018071701A1 (pt) |
| ZA (1) | ZA201902933B (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111419860A (zh) * | 2020-03-19 | 2020-07-17 | 长春市儿童医院 | 一种肾小球分叶状肾病造模方法 |
| CN115215937B (zh) * | 2021-04-15 | 2023-05-26 | 上海麦济生物技术有限公司 | 抗人masp-2抗体及其制备方法和应用 |
| CN117016486B (zh) * | 2023-07-20 | 2024-05-14 | 上海澎立生技医药研究有限公司 | 一种IgA肾病合并膜性肾病的动物模型构建方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE024996T2 (en) * | 2003-05-12 | 2016-01-28 | Helion Biotech Aps | Anti-MASP-2 antibodies |
| US20140056873A1 (en) * | 2004-06-10 | 2014-02-27 | University Of Leicester | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8840893B2 (en) * | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US7626730B2 (en) * | 2006-03-31 | 2009-12-01 | Eastman Kodak Company | Method of making a multilevel halftone screen |
| CA2971474C (en) * | 2009-10-16 | 2022-11-22 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation |
| US9102721B2 (en) * | 2011-01-21 | 2015-08-11 | Fibrogen, Inc. | Therapeutic method |
| NZ709997A (en) * | 2011-04-08 | 2016-03-31 | Univ Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
| US9644035B2 (en) * | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| ME03755B (me) * | 2011-05-04 | 2021-04-20 | Omeros Corp | Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa |
| WO2014144542A2 (en) * | 2013-03-15 | 2014-09-18 | Omeros Corporation | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same |
| ES2829913T3 (es) * | 2013-10-17 | 2021-06-02 | Omeros Corp | Procedimientos de tratamiento de afecciones asociadas con la activación del complemento dependiente de MASP-2 |
| AU2017205453B2 (en) * | 2016-01-05 | 2020-03-12 | Omeros Corporation | Methods for inhibiting fibrosis in a subject in need thereof |
| JOP20170170B1 (ar) * | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
-
2017
- 2017-06-16 JO JOP/2019/0068A patent/JOP20190068A1/ar unknown
- 2017-10-12 EP EP17861108.3A patent/EP3525798A4/en active Pending
- 2017-10-12 SG SG11201902941UA patent/SG11201902941UA/en unknown
- 2017-10-12 GE GEAP201715070A patent/GEP20247587B/en unknown
- 2017-10-12 CA CA3039927A patent/CA3039927C/en active Active
- 2017-10-12 CN CN202310450575.2A patent/CN116726163A/zh active Pending
- 2017-10-12 AU AU2017342428A patent/AU2017342428B2/en active Active
- 2017-10-12 CA CA3210384A patent/CA3210384A1/en active Pending
- 2017-10-12 CN CN201780060710.5A patent/CN110177557A/zh active Pending
- 2017-10-12 BR BR112019007426A patent/BR112019007426A2/pt active Search and Examination
- 2017-10-12 WO PCT/US2017/056386 patent/WO2018071701A1/en unknown
- 2017-10-12 MX MX2019004074A patent/MX2019004074A/es unknown
- 2017-10-12 MA MA046541A patent/MA46541A/fr unknown
- 2017-10-12 UA UAA201904866A patent/UA126908C2/uk unknown
- 2017-10-12 JP JP2019520140A patent/JP6893554B2/ja active Active
- 2017-10-12 KR KR1020197012865A patent/KR102348939B1/ko active IP Right Grant
-
2019
- 2019-04-01 PH PH12019500711A patent/PH12019500711A1/en unknown
- 2019-04-04 CL CL2019000909A patent/CL2019000909A1/es unknown
- 2019-04-11 IL IL265981A patent/IL265981A/en unknown
- 2019-05-10 ZA ZA2019/02933A patent/ZA201902933B/en unknown
- 2019-11-28 CL CL2019003485A patent/CL2019003485A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12019500711A1 (en) | 2019-11-18 |
| CN116726163A (zh) | 2023-09-12 |
| BR112019007426A2 (pt) | 2019-07-02 |
| UA126908C2 (uk) | 2023-02-22 |
| JP6893554B2 (ja) | 2021-06-23 |
| NZ753260A (en) | 2021-11-26 |
| JOP20190068A1 (ar) | 2019-04-01 |
| CL2019000909A1 (es) | 2019-06-14 |
| CL2019003485A1 (es) | 2020-04-13 |
| CA3039927A1 (en) | 2018-04-19 |
| CA3210384A1 (en) | 2018-04-19 |
| AU2017342428B2 (en) | 2021-02-04 |
| KR20190063475A (ko) | 2019-06-07 |
| IL265981A (en) | 2019-06-30 |
| GEP20247587B (en) | 2024-01-25 |
| ZA201902933B (en) | 2023-05-31 |
| MA46541A (fr) | 2019-08-21 |
| CN110177557A (zh) | 2019-08-27 |
| EP3525798A1 (en) | 2019-08-21 |
| KR102348939B1 (ko) | 2022-01-12 |
| MX2019004074A (es) | 2019-06-10 |
| WO2018071701A1 (en) | 2018-04-19 |
| EP3525798A4 (en) | 2020-07-08 |
| JP2019534271A (ja) | 2019-11-28 |
| AU2017342428A1 (en) | 2019-05-23 |
| CA3039927C (en) | 2023-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808242UA (en) | Methods for inhibiting angiogenesis in a subject in need thereof | |
| SG11201903359RA (en) | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma | |
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| SG11201810883TA (en) | Combination therapy | |
| SG11201909081YA (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
| SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201901548SA (en) | Anti-tim-3 antibodies and use thereof | |
| SG11201900745VA (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| SG11201810466PA (en) | Compositions and methods related to engineered fc constructs | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201900606VA (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
| SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11201803834UA (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201901444PA (en) | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods | |
| SG11201903737PA (en) | Neutralizing anti-tl1a monoclonal antibodies | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof |